Renaissance Group LLC Has $2.70 Million Stock Position in HCA Healthcare, Inc. $HCA

Renaissance Group LLC lessened its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 93.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,334 shares of the company’s stock after selling 85,712 shares during the quarter. Renaissance Group LLC’s holdings in HCA Healthcare were worth $2,700,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Clearstead Trust LLC increased its stake in shares of HCA Healthcare by 311.8% in the second quarter. Clearstead Trust LLC now owns 70 shares of the company’s stock worth $27,000 after acquiring an additional 53 shares during the last quarter. Harbor Capital Advisors Inc. raised its stake in shares of HCA Healthcare by 82.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 75 shares of the company’s stock worth $32,000 after purchasing an additional 34 shares in the last quarter. Twin Peaks Wealth Advisors LLC bought a new stake in shares of HCA Healthcare in the 2nd quarter valued at approximately $40,000. Compound Global Advisors LLC acquired a new stake in HCA Healthcare in the third quarter valued at approximately $44,000. Finally, True Wealth Design LLC increased its stake in shares of HCA Healthcare by 179.5% during the 3rd quarter. True Wealth Design LLC now owns 109 shares of the company’s stock worth $47,000 after purchasing an additional 70 shares during the last quarter. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

Shares of HCA opened at $501.89 on Friday. HCA Healthcare, Inc. has a 52 week low of $295.00 and a 52 week high of $527.55. The firm has a market capitalization of $114.53 billion, a P/E ratio of 17.68, a P/E/G ratio of 1.54 and a beta of 1.36. The company has a 50-day simple moving average of $479.97 and a 200-day simple moving average of $442.72.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings results on Tuesday, January 27th. The company reported $8.01 EPS for the quarter, beating the consensus estimate of $7.37 by $0.64. The firm had revenue of $19.51 billion during the quarter, compared to analysts’ expectations of $19.67 billion. HCA Healthcare had a negative return on equity of 409.11% and a net margin of 8.97%.The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.22 EPS. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. As a group, equities analysts forecast that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 17th will be given a dividend of $0.78 per share. This is an increase from HCA Healthcare’s previous quarterly dividend of $0.72. The ex-dividend date is Tuesday, March 17th. This represents a $3.12 annualized dividend and a dividend yield of 0.6%. HCA Healthcare’s dividend payout ratio (DPR) is presently 10.99%.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, EVP Michael S. Cuffe sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $498.09, for a total transaction of $747,135.00. Following the completion of the transaction, the executive vice president owned 30,003 shares in the company, valued at $14,944,194.27. This trade represents a 4.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have commented on the stock. UBS Group increased their target price on shares of HCA Healthcare from $525.00 to $598.00 and gave the stock a “buy” rating in a research report on Wednesday, January 28th. Robert W. Baird raised their price objective on HCA Healthcare from $423.00 to $450.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Cantor Fitzgerald increased their price target on HCA Healthcare from $525.00 to $588.00 and gave the company an “overweight” rating in a report on Wednesday, January 28th. Sanford C. Bernstein reiterated a “market perform” rating on shares of HCA Healthcare in a report on Wednesday, January 28th. Finally, Wells Fargo & Company raised their price target on HCA Healthcare from $452.00 to $481.00 and gave the company an “equal weight” rating in a research report on Friday, January 30th. Sixteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $521.55.

About HCA Healthcare

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.